Capricor culls COVID-19 vax work but eyes phase 3 for Duchenne therapynews2022-03-10T19:07:14+00:00March 10th, 2022|FierceBiotech|
MorphoSys cans US R&D to consolidate work in Germany, taking $254M chargenews2022-03-10T18:36:07+00:00March 10th, 2022|FierceBiotech|
Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot ‘expeditiously’news2022-03-10T15:18:42+00:00March 10th, 2022|FierceBiotech|
Moderna doses 2nd arm of phase 2 booster study combining Spikevax with omicron-busting shotnews2022-03-10T14:39:44+00:00March 10th, 2022|FierceBiotech|
Roche-partnered Scenic Biotech snags $31M to study 3 rare disease drugsnews2022-03-10T14:25:34+00:00March 10th, 2022|FierceBiotech|
Morningside rolls up a pair of biotechs to birth clinical-phase inflammatory disease playernews2022-03-10T14:09:32+00:00March 10th, 2022|FierceBiotech|
Venatorx hits goal in antibiotic phase 3, clearing path to FDAnews2022-03-10T13:06:51+00:00March 10th, 2022|FierceBiotech|
Intellia’s CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launchnews2022-03-09T21:31:15+00:00March 9th, 2022|FierceBiotech|
We have achieved peak biotech formation. It’s time for ‘musical chairs’news2022-03-09T19:32:22+00:00March 9th, 2022|FierceBiotech|
Twist’s antibodies to wind up with Kriya’s AAV gene therapies in new pactnews2022-03-09T15:25:44+00:00March 9th, 2022|FierceBiotech|